IRIS
FALOPPI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.875
EU - Europa 871
AS - Asia 276
AF - Africa 18
Continente sconosciuto - Info sul continente non disponibili 3
Totale 3.043
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.875
IT - Italia 193
UA - Ucraina 193
SE - Svezia 122
IE - Irlanda 107
TR - Turchia 99
DE - Germania 88
DK - Danimarca 76
CN - Cina 75
FI - Finlandia 56
SG - Singapore 52
KR - Corea 41
GB - Regno Unito 26
CI - Costa d'Avorio 15
IN - India 9
FR - Francia 4
DZ - Algeria 3
EU - Europa 3
BE - Belgio 2
NL - Olanda 2
CZ - Repubblica Ceca 1
RS - Serbia 1
Totale 3.043
Salva come PNG Salva come JPEG
Città #
Chandler 253
Fairfield 219
Jacksonville 210
Ashburn 128
Wilmington 124
Dublin 107
Seattle 89
Woodbridge 89
Centro 73
Houston 69
New York 69
Cambridge 66
Ann Arbor 61
Boardman 56
Des Moines 53
Lawrence 44
Princeton 44
San Mateo 44
Turin 35
Helsinki 17
San Diego 16
Abidjan 15
Beijing 15
London 9
Pune 9
Wuxi 8
Izmir 7
Singapore 7
Los Angeles 6
Washington 6
Norwalk 5
Shanghai 5
Kilburn 4
Wuhan 4
Guangzhou 3
New Bedfont 3
Portland 3
Prescot 3
Amsterdam 2
Brussels 2
Chicago 2
Chiswick 2
Como 2
Fayetteville 2
Florence 2
Isola della Scala 2
Jinhua 2
Milan 2
Modena 2
Montesilvano 2
Roseto degli Abruzzi 2
Venice 2
Yiwu 2
Acton 1
Ascoli Piceno 1
Belgrade 1
Chizhou 1
Clifton 1
Cupra Marittima 1
Dalian 1
Dongyang 1
Falkenstein 1
Foshan 1
Frankfurt (Oder) 1
Hanover 1
Heze 1
Hounslow 1
Islington 1
Matelica 1
Nanjing 1
Nantong 1
Olomouc 1
Pesaro 1
Porto 1
Qingdao 1
San Francisco 1
San Giuliano 1
Santa Clara 1
Seoul 1
Stamford 1
Suzhou 1
Tiantai Chengguanzhen 1
Torre Del Greco 1
Xuzhou 1
Totale 2.039
Salva come PNG Salva come JPEG
Nome #
The role of Aspirin as antitumoral agent for heavily pre-treated metastatic colorectal cancer patients receiving capecitabine monotherapy. BMC Cancer 127
Immunotherapy in genitourinary cancers: Where are we going? 116
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 115
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy 112
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment 94
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 82
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 82
The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. 80
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management 80
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 78
Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. 78
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 77
CANCER STEM CELL GENETIC PROFILE AS PREDICTOR OF RELAPSE IN RADICALLY RESECTED COLORECTAL CANCER 77
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 77
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. 76
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 75
The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer 74
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 72
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management 72
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 71
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab 69
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 66
Trattamento del carcinoma del pancreas. Attualità e prospettive 66
Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. 66
Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer 66
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 66
Panitumumab for the treatment of metastatic colorectal cancer: A review 65
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 65
Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. 64
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 63
Gastric cancer: Therapeutic choices in advanced disease 62
Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients 61
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 61
The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for advanced renal cell carcinoma patients receiving first-line sunitinib 57
Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. 56
Selecting the best treatment for an individual patient. 56
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 54
Tracking the 2015 gastrointestinal cancers symposium: Bridging cancer biology to clinical gastrointestinal oncology 54
The Tower of Babel of liver metastases from colorectal cancer: Are we ready for one language? 53
Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: It is not about the destination, it is about the journey 53
Selected news from the 2014 Genitourinary Cancers Symposium: Translating novel strategies into clinical practice 52
Cetuximab: still an option in the treatment of pancreatic cancer? Expert Opin Biol Ther. 2013 May;13(5):791-801 49
Palliative treatment 48
Predictive factors for sunitinib treatment response in advanced renal cell carcinoma: are we really making steps forward? 45
Totale 3.132
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.846
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.846
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020239 0 0 35 0 40 0 40 4 41 2 16 61
2020/2021784 47 78 79 4 135 67 73 52 57 92 67 33
2021/2022357 28 82 7 6 2 23 15 24 20 54 26 70
2022/2023745 51 105 58 55 47 119 1 44 168 3 78 16
2023/2024388 59 4 39 50 60 104 6 4 1 6 7 48
2024/202574 74 0 0 0 0 0 0 0 0 0 0 0
Totale 3.132